

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/943,712	08/31/2001	Takafumi Kohama	00626A/HG	1333		
1933	7590 03/26/2002					
FRISHAUF,	HOLTZ, GOODMAN	EXAM	EXAMINER			
LANGER & C	VENUE		JONES, DV	JONES, DWAYNE C		
25TH FLOOR NEW YORK.	NY 10017-2023	ART UNIT	PAPER NUMBER			
,			1614	· ., <u>.</u>		
		DATE MAILED: 03/26/2002				

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Applicati r	N. (1)	Applicant(s)				
		09/943,712		KOHAMA ET AL.				
•	Office Action Summary	Examin r		Art Unit				
		Dwayne C	Jones	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status	Posnonsivo to communication(s) filed on							
1) <u></u> 2a)□	Responsive to communication(s) filed on This action is FINAL . 2b)⊠ Th	· his action is n	on-final					
	,—			secution as to the	a marite is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
•	Claim(s) 1-28 is/are pending in the application							
	4a) Of the above claim(s) is/are withdra	wn from cons	sideration.					
·	5) Claim(s) is/are allowed.							
	Claim(s) <u>1-28</u> is/are rejected.							
	Claim(s) is/are objected to.							
-	Claim(s) are subject to restriction and/c on Papers	or election red	quirement.					
· · · _	The specification is objected to by the Examine	er.						
•	The drawing(s) filed on is/are: a) ☐ acce		biected to by the Exam	niner.				
,_	Applicant may not request that any objection to the		-					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)⊠ All b)□ Some * c)□ None of:								
1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No							
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>4</u>	5		(PTO-413) Paper No(atent Application (PTC				

Application/Control Number: 09/943,712 Page 2

Art Unit: 1614

DETAILED ACTION

Status of Claims

- 1. Claims 1-28 are pending.
- 2. Claims 1-28 are rejected.

Information Disclosure Statement

3. The information disclosure statement filed on November 27, 2001 and January 15, 2002 have been reviewed and considered, see enclosed copies of PTO FORMs 1449.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 6. Claims 1-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bocan of WO 97/16184 in view of Kamiya et al. of EP 866,059 A1. Bocan teaches of

the combination of inhibitors of acyl-CoA: cholesterol acyltransferase, (ACAT) inhibitors and HMG-CoA-reductase inhibitors. Bocan also teach that these compounds are known to lower LDL cholesterol as well as treating atherosclerotic disease, (see abstract and pages 1-3). In fact, Bocan specifically teaches of the following HMG-CoA-reductase inhibitors of atorvastatin, lovastatin, simvastatin, pravastatin and fluvastatin, (see pages 3 and 4). Kamiya et al. teach of inhibitors of acyl-CoA: cholesterol acyltransferase, (see abstract and page 1). In particular, Kamiya et al. teach of the treatment of arteriosclerosis, hyperlipemia, and cardiovascular ischemic disease with the compound N-(1-Octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, (see Example 4). Since both of these prior art references are directed to treating the very same ailment it the skilled artisan would have been motivated to substitute one ACAT inhibitor for another. In addition, the ACAT inhibitors of Kamiya et al. possess improved oral absorptions, strong anti-hyperlipemia and anti-arteriosclerosis effects, (see page 1, lines 50-55).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Application/Control Number: 09/943,712

Art Unit: 1614

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-

Page 4

WE C. JONES

Tech. Ctr. 1614

March 20, 2002